In a research in breast most cancers cells, the combination of lapatinib, a twin HER2/neu and EGFR tyrosine kinase inhibitor, with INK128 prevented both HER2 and HER3 phosphorylation induced by INK128 and manufactured synergistic induction of mobile death in several HER2-optimistic cell traces immune to trastuzumab and lapatinib. In vivoLycorineThe